A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate To Severe Chronic Hand Eczema Refractory to Topical Corticosteroid Therapy
Phase of Trial: Phase II
Latest Information Update: 26 Sep 2019
Price : $35 *
At a glance
- Drugs Gusacitinib (Primary)
- Indications Eczema
- Focus Therapeutic Use
- Sponsors Asana BioSciences
- 23 Sep 2019 Status changed from active, no longer recruiting to recruiting.
- 11 Sep 2019 Status changed from recruiting to active, no longer recruiting.
- 09 Jan 2019 Status changed from not yet recruiting to recruiting.